In addition, the combination of CART19 and CART123 prevented antigen-loss relapse in xenograft models, while the CD19/CD123 bicistronic CAR-T cell product had superior in vivo activity against B-ALL as compared to each single-expressing CAR-T or pooled combination CAR-T (86). The gene discussed is CD19; the disease is acute lymphoblastic leukemia.